Protagonist Therapeutics, Inc
PTGXDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 5, 2026
TomorrowMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
PTGX Earnings Report
EPS Est: $2.11 | FQ end 2026-06
How PTGX's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PTG-300 | Phase 2 | Polycythemia Vera | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Protagonist Therapeutics, Inc's drug pipeline?→
CatalystAlert tracks 1 drug candidate in Protagonist Therapeutics, Inc's (PTGX) pipeline across Phase 2. Its lead program is PTG-300 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Protagonist Therapeutics, Inc's next FDA catalyst?→
Protagonist Therapeutics, Inc's (PTGX) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PTGX biotech catalysts?→
Add PTGX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Protagonist Therapeutics, Inc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.